Table 2.
Risk of pancreatic cancer in association with aspirin use – Roswell Park Cancer Institute, Buffalo, NY 1982–1996.
| Cases n (%) | Controls n (%) | Crude OR (95% CI) | Adjusted OR1 (95% CI) | |
| All | ||||
| Non-Regular User | 108(55.7) | 327(56.2) | 1.00 | 1.00 |
| Regular User2 | 86 (44.3) | 255(43.8) | 1.02 (0.74, 1.42) | 1.00 (0.72, 1.39) |
| Dosage Used | ||||
| 1–6 tabs/wk3 | 61 (31.4) | 157(26.9) | 1.18 (0.82, 1.70) | 1.15 (0.79, 1.67) |
| 7+ tabs/wk3 | 25 (12.9) | 98 (16.8) | 0.87 (0.51, 1.48) | 0.85 (0.49, 1.45) |
| Duration of Use | ||||
| 0.5–10 years3 | 37 (19.1) | 137(23.6) | 0.82 (0.54, 1.25) | 0.82 (0.54, 1.26) |
| 11+ years3 | 49 (25.3) | 117(20.1) | 1.27 (0.85, 1.89) | 1.21 (0.81, 1.82) |
| Tablet-years of Use3 | ||||
| 1–10 tablet years | 69 (35.6) | 176 (30.2) | 1.19 (0.83, 1.69) | 1.15 (0.80, 1.65) |
| 11+ tablet years | 17 (8.8) | 79 (13.6) | 0.65 (0.37, 1.15) | 0.65 (0.37, 1.16) |
| Men | ||||
| Non-Regular User | 58 (54.7) | 174 (54.7) | 1.00 | 1.00 |
| Regular User2 | 48 (45.3) | 144 (45.2) | 1.00 (0.64, 1.56) | 0.99 (0.64, 1.5) |
| Dosage Used3 | ||||
| 1–6 tabs/wk | 31 (29.2) | 87 (27.4) | 1.07 (0.64, 1.77) | 1.05 (0.63, 1.75) |
| 7+ tabs/wk | 17 (16.0) | 57 (17.9) | 0.90 (0.48, 1.66) | 0.91 (0.49, 1.70) |
| Duration of Use3 | ||||
| 0.5–10 years | 27 (25.5) | 81 (25.5) | 1.00 (0.59, 1.69) | 1.03 (0.60, 1.75) |
| 11+ years | 21 (19.8) | 63 (19.8) | 1.00 (0.56, 1.78) | 0.95 (0.53, 1.72) |
| Tablet-years of Use3 | ||||
| 1–10 tablet years | 43 (40.6) | 113 (35.5) | 1.14 (0.72, 1.81) | 1.12 (0.70, 1.78) |
| 11+ tablet years | 5 (4.7) | 31 (9.7) | 0.48 (0.18, 1.30) | 0.52 (0.19, 1.40) |
| Women | ||||
| Non-Regular User | 50 (56.8) | 153 (59.0) | 1.00 | 1.00 |
| Regular User2 | 38 (43.2) | 111 (42.0) | 1.05 (0.64, 1.71) | 1.01 (0.62, 1.67) |
| Dosage Used3 | ||||
| 1–6 tabs/wk | 30 (34.1) | 70 (26.5) | 1.31 (0.77, 2.24) | 1.29 (0.75, 2.23) |
| 7+ tabs/wk | 4 (9.1) | 41 (15.5) | 0.77 (0.24, 2.40) | 0.67 (0.21, 2.14) |
| Duration of Use3 | ||||
| 0.5–10 years | 10 (11.4) | 56 (21.2) | 0.55 (0.26, 1.15) | 0.55 (0.26, 1.16) |
| 11+ years | 28 (31.8) | 54 (20.5) | 1.59 (0.91, 2.77) | 1.52 (0.86, 2.69) |
| Tablet-years of Use3 | ||||
| 1–10 tablet years | 26 (29.5) | 63 (23.9) | 1.26 (0.72, 2.21) | 1.25 (0.70, 2.20) |
| 11+ tablet years | 12 (13.6) | 48 (18.2) | 0.77 (0.38, 1.55) | 0.72 (0.35, 1.49) |
1. Odds ratio adjusted for age, packyears of smoking and family history of pancreatic cancer. 2. Regular use defined as self-reported use for at least once a week for six consecutive months. 3. Among regular users.